![](/img/cover-not-exists.png)
LBA30Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
Finn, R.S., Kudo, M., Cheng, A-L., Wyrwicz, L., Ngan, R., Blanc, J-F., Baron, A.D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K-H., Qin, S., Minoshima, Y., Funahashi, Y., Ren, M., Dairiki, R., SachdevVolume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx440.022
Date:
September, 2017
File:
PDF, 51 KB
english, 2017